Shamburg News · 8-K filed Nov 10, 2026, 4:06 PM EST
Prime Medicine Estimates $61.2 Million Cash and Short-Term Investments as of September 30, 2026
PRME · Prime Medicine, Inc.
- Earnings
- Other event
- Materiality: medium
On November 10, 2026, Prime Medicine, Inc. announced preliminary unaudited estimates of approximately $61.2 million in cash, cash equivalents, and short-term investments as of September 30, 2026, excluding about $13.7 million of restricted cash. The company has not completed its quarter-end financial close, and the estimates are not audited or reviewed by PricewaterhouseCoopers LLP. Complete results will be included in the Form 10-Q for the quarter ended September 30, 2026. The same day the company posted an updated corporate presentation, furnished as Exhibit 99.1.
Source: SEC EDGAR, Form 8-K, Items 2.02, 8.01, 9.01, accession 0001628280-26-072713.
Written from the filing by Shamburg Markets. Figures are as reported by the company.